JAPAN – Modulus Discovery, Inc., a Boston, MA- and Tokyo, Japan-based preclinical-stage computation-driven drug discovery company, closed a Series C funding round in the amount of 2.34B JPY (approximately $20.4M USD).
Backers included Green Coinvest Investment Limited Partnership., SBI Group., Heights Capital Management, Inc., and existing shareholders including UTokyo Innovation Platform Co., Ltd., JAFCO Group Co., Ltd., Keio Innovation Initiative, Inc. (KII), and Fast Track Initiative, Inc. Modulus has raised to date, a total of 5.86B JPY (approximately $51M USD). The company will use the proceeds to further its portfolio of R&D programs driven by its proprietary computational drug discovery platform and globally networked operational model. In addition to accelerating its existing pipeline of over 10 R&D programs, Modulus aims to increase its business value through expansion of its platform infrastructure, collaborations with industry and academic partners, and increase personnel in R&D and operations to deliver innovative drug candidates through clinical partnerships and additional drug discovery collaborations.Led by S. Roy Kimura, Ph.D., Co-founder and CEO, Modulus Discovery is a preclinical-stage computation-driven drug discovery company pursuing its proprietary portfolio of small-molecule discovery programs and collaborations through integration of its core biology insights, discovery platform, and scalable networked operations. Modulus is focused on the efficient delivery of medicines for patients and their families with unmet medical needs in areas including oncology, chronic inflammation / immune disorders, and rare genetic conditions.04/03/2022
